HPAPIおよび細胞毒性薬製造市場：原薬別、製造場所別、薬剤タイプ別、薬理分子タイプ別、用途別、地域別：規模、シェア、見通し、機会分析（2022年～2030年）

当レポートでは、世界のHPAPIおよび細胞毒性薬製造市場について調査し、市場の概要とともに、原薬別、製造場所別、薬剤タイプ別、薬理分子タイプ別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査目的・前提条件

第2章 市場概要

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
  • 市場内訳：原薬別
  • 市場内訳：製造場所別
  • 市場内訳：薬剤タイプ別
  • 市場内訳：薬理分子タイプ別
  • 市場内訳：用途別
  • 市場内訳：地域別
• コヒーレントオポチュニティマップ（COM）

第3章 市場力学、規制、および動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場の機会
• 影響分析
• 規制シナリオ
• PEST分析
• 最近の製品発売/承認
• 疫学
• 合併と買収

第4章 世界のHPAPIおよび細胞毒性薬製造市場-COVID-19パンデミックの影響

第5章 世界のHPAPIおよび細胞毒性薬製造市場：原薬別、2017年～2030年（10億米ドル）

• イントロダクション
• 化学ベースのHPAPI
• 生物学的製剤ベースのHPAPI

第6章 世界のHPAPIおよび細胞毒性薬製造市場：製造場所別、2017年～2030年（10億米ドル）

• イントロダクション
• 内製
• アウトソーシング

第7章 世界のHPAPIおよび細胞毒性薬製造市場：薬剤タイプ別、2017年～2030年（10億米ドル）

• イントロダクション
• 新規HPAPI
• ジェネリックHPAPI

第8章 世界のHPAPIおよび細胞毒性薬製造市場：薬理分子タイプ別、2017年～2030年（10億米ドル）

• イントロダクション
• 低分子
• 生物製剤

第9章 世界のHPAPIおよび細胞毒性薬製造市場：用途別、2017年～2030年（10億米ドル）

• イントロダクション
• 腫瘍学
• 呼吸器
• 眼科疾患
• その他

第10章 世界のHPAPIおよび細胞毒性薬製造市場：地域別、2017年～2030年（10億米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第11章 競合情勢

• 企業プロファイル
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Lonza Group
  • Corden Pharma International
  • Evonik Industries AG
  • Flamma Group
  • Merck KGaA
  • CARBOGEN AMCIS
  • Catalent, Inc.
  • Piramal Enterprises Ltd.
  • AbbVie Inc.
  • Fareva Group
  • Cerbios-Pharma SA
  • Novasep
  • Ajinomoto Bio-Pharma
  • PCI Pharma Services
  • Sterling Pharma Solutions
  • Heraeus Holding
  • Polpharma Biologics
  • Helsinn Healthcare SA
  • Seqens
  • Cambrex Corporation
• アナリストの見解

第12章 セクション

Highly potent active pharmaceutical ingredients (HPAPI) has an increasingly significant share of the pharmaceutical drug pipeline including anti-cancer treatments. Manufacturing highly potent APIs in large volumes requires extensive project experience with HPAPIs and a strong track record for audits and supply security.

Cytotoxic drugs are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms.

Market Dynamics

Market players are engaged in inorganic activities, such as acquisitions, in order to expand its product portfolio, this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in January 2019, Flamma Group, a life science company, acquired Teva's Chemical Synthesis Center, the 40,000 sq. ft. cGMP facility in Malvern (U.S.). This laboratory and manufacturing site possesses a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 5 standard cGMP kilo lab suites, and 1 cGMP HPAPI kilo lab suite.

Key players are focusing on receiving authorizations for their manufacturing facilities, from the regulatory authorities, and this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in December 2019, Cerbios-Pharma SA announced the authorization by Swissmedic of its cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs).

Moreover, in December 2019, Piramal Pharma Solutions, a division of Piramal Enterprises ltd., expanded its manufacturing facility in Riverview, Michigan, with an investment of approximately US$ 32 million to develop and manufacture potent and non-potent active pharmaceutical ingredients (API).

Key features of the study:

• This report provides an in-depth analysis of the global HPAPIs and cytotoxic drugs manufacturing market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players

• It profiles leading players in the global HPAPIs and cytotoxic drugs manufacturing market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation

• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

• The global HPAPIs and cytotoxic drugs manufacturing market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts

• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HPAPIs and cytotoxic drugs manufacturing market

Detailed Segmentation:

• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin:
  • Chemical-based HPAPIs
  • Biologic-based HPAPIs
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location:
  • In-house Manufacturing
  • Outsourcing
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type:
  • Novel HPAPIs
  • Generic HPAPIs
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule:
  • Small Molecules
  • Biologics
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application:
  • Oncology
  • Respiratory
  • Ophthalmic Disorders
  • Others
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Teva Pharmaceutical Industries Ltd.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Pfizer, Inc.
  • Lonza Group
  • CordenPharma International
  • Evonik Industries AG
  • Flamma Group
  • Merck KGaA
  • CARBOGEN AMCIS
  • Catalent, Inc.
  • Piramal Enterprises Ltd.
  • AbbVie Inc.
  • Fareva Group
  • Cerbios-Pharma SA
  • Novasep
  • Ajinomoto Bio-Pharma
  • PCI Pharma Services
  • Sterling Pharma Solutions
  • Heraeus Holding
  • Polpharma Biologics
  • Helsinn Healthcare SA
  • Seqens
  • Cambrex Corporation

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Origin
  • Market Snippet, By Manufacturing Location
  • Market Snippet, By Drug Type
  • Market Snippet, By Type of Pharmacological Molecule
  • Market Snippet, By Application
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Regulatory Scenario
• PEST Analysis
• Recent Product Launch/Approval
• Epidemiology
• Mergers and Acquisitions

4. Global HPAPIs and Cytotoxic Drugs Manufacturing Market - Impact of Coronavirus (Covid-19) Pandemic

• Impact on Supply Chain
• Impact on Research and Development
• Government Initiatives

5. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Chemical-based HPAPIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Biologic-based HPAPIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

6. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• In-house Manufacturing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Outsourcing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

7. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Novel HPAPIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Generic HPAPIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

8. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Small Molecules
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

9. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Respiratory
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Ophthalmic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

10. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2030
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• U.S.
• Canada
• Latin America
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• South Africa
• Central Africa
• North Africa

11. Competitive Landscape

• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Pfizer, Inc.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Lonza Group
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Corden Pharma International
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Evonik Industries AG
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Flamma Group
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Merck KGaA
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • CARBOGEN AMCIS
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Catalent, Inc.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Piramal Enterprises Ltd.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • AbbVie Inc.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Fareva Group
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Cerbios-Pharma SA
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Novasep
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Ajinomoto Bio-Pharma
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • PCI Pharma Services
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Sterling Pharma Solutions
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Heraeus Holding
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Polpharma Biologics
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Helsinn Healthcare SA
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Seqens
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Cambrex Corporation
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
• Analyst Views

12. Section

• References
• Research Methodology
• About us and Sales Contact